(News Bulletin 247) – The title Abivax evolves on a hesitant note Thursday on the Paris Stock Exchange following the publication of annual results judged without great surprise by analysts.

Shortly before 12:00 p.m., the biotech company’s stock advanced 0.9% after falling 7% during the morning.

Abivax reported this morning an operating loss of 56.6 million euros for the 2022 financial year, compared to -42.6 million euros in 2021, due to the increase in its investments. in R&D and its general and administrative expenses.

In a note of reactions, the teams of Degroof Petercam evoke a publication ‘without surprise’.

‘The only highlight is the announcement of an extension of financial visibility until the second quarter of 2024’, estimates the Brussels stock exchange company.

Abivax, which specifies that its cash consumption currently amounts to around seven million euros per month, underlines that its capital increase of 130 million euros subscribed in February ensures its financing until the end of the second quarter of 2024. .

Analysts at Degroof Petercam, who have a buy recommendation for the stock, say they have accordingly adjusted their price target for the stock from 13.5 to 16.2 euros.

Thanks in particular to promising clinical results in ulcerative colitis, the Abivax stock has posted a gain of more than 99% since the beginning of the year.

Copyright (c) 2023 News Bulletin 247. All rights reserved.